New Long-Acting Injectable HIV Therapies

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial – The Lancet (free)

Commentary: Long-Acting Injectable HIV Regimens Show Promise – Physician’s First Watch (free) AND Injections ‘next revolution’ in HIV: study – BBC (free)